The vaccine was well tolerated, and no safety concerns related to the vaccine were identified, according to the data.
British-Swedish drugmaker AstraZeneca on Wednesday revised down by three percentage points the effectiveness of its Covid vaccine after American authorities raised concerns that results reported from its USA trial were outdated. While overall effectiveness ebbed slight down, efficacy in people 65 years old and over jumped from 80 to 85 percent.
Participants were randomised on a 2:1 ratio between the vaccine and placebo group.
Europe's drugs regulator said on Thursday its safety panel will call a meeting of experts on March 29 to further study the reported cases of blood clots linked to the COVID-19 vaccine developed by AstraZeneca and Oxford University.
AstraZeneca's update followed concerns from an independent expert safety panel, called the Data and Safety Monitoring Board, that the U.S. trial results released Monday could be partially based on "outdated data".
United States scientists were taken aback on Tuesday by a midnight news release issued from the National Institutes of Health (NIH) raising doubts about the company's announcement a day earlier that the vaccine was 79 per cent effective at preventing Covid-19 in the USA trial.
The revised figures are based on trials involving 32,400 participants in the US, Chile and Peru, of whom 190 people became infected with COVID-19.
"We look forward to filing our regulatory submission for Emergency Use Authorisation in the United States and preparing for the rollout of millions of doses across America".
Spring breakers arrested for death of woman who was allegedly drugged, raped
Collier was later found in the area, as police identified him wearing the same trousers as in the surveillance footage. He allegedly said "that he went along with [Taylor] as they planned to have sex with the victim", the report said.
As with other vaccine trials, the company was looking to see how many vaccinated people got COVID-19 symptoms as compared to unvaccinated people.
AstraZeneca says it plans to release the results of its primary analysis within 48 hours.
The earlier "outdated" or incomplete data was based on 141 COVID-19 infections up until February 17.
"A key secondary endpoint, preventing severe or critical disease and hospitalization, demonstrated 100% efficacy".
NIAID Director Anthony Fauci told ABC News' "Good Morning America" that the vaccine is likely very good.
Vials with Covid-19 Vaccine stickers attached and syringes with the logo of British pharmaceutical company AstraZeneca.
The European Medicines Agency deemed the vaccine safe and said it was not associated with blood clotting generally - but added it could not rule out a link to two highly rare forms of clotting, and suggested these risks be mentioned on a warning label.
"Health Canada has assessed the available data on the reported events and has determined that the AstraZeneca COVID-19 Vaccine and COVISHIELD (the version of the AstraZeneca COVID-19 Vaccine manufactured by the Serum Institute of India that is now being distributed in Canada) have not been associated with an increase in the overall risk of thrombosis", the regulator wrote.